Zhengye Biotechnology Holding Ltd. has released its financial results for the fiscal year ending December 31, 2024. The company reported net revenues of RMB 186.356 million ($25.531 million), marking a decrease from RMB 211.651 million in 2023 and RMB 260.269 million in 2022. The cost of revenues for 2024 was RMB 95.061 million ($13.023 million), compared to RMB 94.143 million in the previous year and RMB 112.390 million in 2022. The company, which specializes in veterinary vaccines with a focus on livestock, has not indicated any trends or uncertainties that might materially affect its financial condition or operations in the future. Zhengye Biotechnology emphasizes that its operating results for any given period are not necessarily indicative of future outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.